Otitis Media
Otitis media (OM) is inflammation of the middle ear which may present as either acute otitis media (AOM) or otitis media with effusion (OME). AOM exhibits rapid onset, middle ear effusion and signs and symptoms of middle ear inflammation including fever, otalgia, otorrhea, or irritability 1 , whereas OME is middle ear effusion in the absence of symptoms of acute infection. 2 Clearly, on the basis of likelihood of presentation for treatment in non-Indigenous children, AOM maybe over-reported, by 22%-50% 3,4 whilst OME maybe underreported. In a recent prospective study, it was demonstrated that the frequency of AOM episodes is age related, with an average of 1.97, 1.67 and 1.07 episodes occurring per year for children 6-11 months of age, 12-23 months of age and 24-35 months of age respectively 5 . For older children, the frequency of new onset OME is greater than that reported for AOM. In a cohort of 242 children aged 1-8.6 years, the frequency of new onset OME was 4-fold greater than AOM 6 and this finding is consistent with previous data indicating 50% of OME occurred subsequent to AOM. 7 
Diagnostic challenge
OM and upper respiratory tract infections (URTIs) share many common symptoms and are often coincident, increasing the variability of diagnosis for AOM. AOM is temporally associated with upper respiratory tract infections or cold-like illnesses in 50-70% of all new AOM cases 8, 9 whilst between 29%-61% of all cases of URTI may develop into OM. 5, 10, 11 In clinical practice, URTI symptoms and either rhinitis or cough were observed by French general practitioners in almost 90% of suspected or diagnosed AOM.
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Other final without track changes OM can be difficult to confirm since otoscopic observation of tympanic membrane changes including bulging, erythema or opacity of the tympanic membrane 12, 13 are not always characteristic of AOM. Successful otoscopic examination of very young distressed children, often on repeated occasions, further increases the diagnostic challenge for clinicians since the peak incidence for AOM is between 6 and 18 months of age.
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The uncertainty of clinical diagnosis of AOM is demonstrated by a US study in which general practitioners stated certainty of their diagnosis for AOM in only 58% of infant cases, 66% of toddler cases and 73% of AOM cases in older children. 16 Furthermore, although 78% of diagnoses of AOM in children 1-4 years of age were shown to be consistent between the general practitioner and otolaryngologists, up to one third of the incorrect diagnoses were identified as normal ears by the otolaryngologists.
Otitis media; a polymicrobial disease OM is a multifactorial disease 17 with an extensive causal basis, including demographic, social, environmental, immunological and microbial risk factors. 18 The development and growth of the eustachian tube in the first two years favours episodes of tubal blockage, often exacerbated by pollutants, allergies and viral infections. 19 Abnormality of the eustachian tube is a contributing factor to a child's susceptibility to recurrent episodes of AOM and OME. 20 Equalisation of middle ear pressure through reopening the eustachian tube insufflates nasopharyngeal bacteria into the tympanic cavity. It is important to note that clinically healthy middle ears may also contain bacteria or evidence of bacterial biofilms, 21 possibly resulting from transfer from the nasopharynx during normal events such as sniffing. 22 and enterovirus (34.4%) 5 . Alper and co-workers 25 also confirmed the high frequency of association of OM with rhinovirus (44%) and RSV (56%) 25 . In unwell children attending hospital for AOM, viruses common for URTI were detected in 35% patients acutely ill with AOM. In these children, the most commonly identified viruses, using viral culture, were RSV (41%), influenza (types A, B and C combined) 23% and adenovirus (17%).
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Improved viral detection has also resulted in identification of a broader range of respiratory viruses including human metapneumonia virus (hMPV), 26 corona virus (HCoV-NL63) 27 , and bocavirus 28 as causal for either URTIs or OM, although their relative contribution to OM is yet to be determined. Caution regarding these viruses and their potential association with OM and URTIs is necessary since these viruses can also be detected in asymptomatic children 8 or, in the case of rhinovirus, over a prolonged period. 10 The failure to detect URTIs symptoms in only 2-3% of AOM episodes in otherwise healthy children may potentially indicate that the AOM arose through bacterial or other inflammatory pathogenesis. The association of OME and URTIs is reflected in the observation that only 0.6% of new onset OME episodes were diagnosed 30 days prior to URTI establishment.
5 Table 1 provides a summary of the contribution of viral infections to AOM.
Role of bacteria
Bacterial co-infection with upper respiratory tract viruses, rather than viral or bacterial pathogenesis alone predominates and is reported to range from 28% to 70% in the middle ear and nasopharynx. 23, 24, 29 The three most commonly recovered bacteria associated with OM are Staphylococcous pneumoniae, Haemophilus influenzae and Moraxella catarrhalis, which are all commensal within the nasopharynx, with the majority of H. influenzae isolated being non-typeable. 29, 30 Bacteria are recovered in up to 90% of hospital reported cases of AOM, with S. the first year of life and AOM from all causes has a peak incidence between 6 and 12 months of age as determined from culture of the middle ear fluid. 37 In contrast,
Indigenous Australian children at high risk of OM, experience high rates of AOM between 3-6 weeks of age, with tympanic membrane perforation occurring in about 20% (2) of children. 36 Overall, 9 out of 10 Aboriginal children aged 6-30 months had clinical signs of OM and tympanic membrane perforation had occurred in 40% of children by 18 months of age. Unfortunately, in these older children, AOM is often asymptomatic until discharge from the ear is visible. 38, 39, 40 OM exhibits a high rate of recurrence, with three or more episodes of AOM reported in 50% of children aged three years rising to 65% for children aged 5 years of age whilst OME recurs in 50% of children within 24 months 14 . For Indigenous Australian children at high risk of OM, the rate of recurrence of AOM and OME is better described as persistent AOM. For these children, despite antibiotic treatment, AOM episodes do not typically present as acute in onset or short in duration. Indeed, persistent suppuration remained present for 77% of children for up to 14 days after initial diagnosis. 41 In the first few years of life, approximately 20% of children that experience AOM will not respond to antibiotic therapy 42, 43 and in these children, AOM may continue to either persist or recur 42 . There is ongoing controversy as to whether this ongoing AOM results from persistence of the original infection or establishment of new infection, however it has been reported that new infections may cause up to 54% of recurrent AOM episodes, within one month of antibiotic treatment whilst bacterial relapse of the original infection comprised approximately 28% of all cases. 43 Early clinical recurrence of AOM within three weeks of initial treatment is associated with nasopharyngeal carriage of S. pneumoniae 44 although H. influenzae is clearly associated with recurrent AOM 37 and was the most prevalent pathogen (42%) observed in both bilateral and unilateral OM. 45 Extensive geographical variation has been observed in bacterial carriage 46 and disease, 47 as well as the pneumococcal serotypes 48 and the relative proportion of S.
pneumoniae, H. influenzae and M. catarrhalis that are responsible for OM. 45, 49, 50 This variation adds to the complexity of developing an efficacious vaccine against OM
The proportion of AOM cases attributable to bacteria is summarised in Table 1 .
Biofilms
Bacterial biofilms, microbial communities that attach to the mucosal surface and produce their own 3-dimensional structures covered in an exopolysaccharide matrix, are involved with a number of otolaryngological conditions. 51 Pneumococcal biofilms have been visualised in 92% of middle ear mucosal biopsy samples from children symptomatic for OME 52 and H. influenzae isolates obtained from patients with recurrent AOM, form biofilms in vitro 53 . It is important to recognise that middle ear biofilms maybe present in up to 9% of healthy ears 54 without provoking symptoms.
Biofilms are hypothesised to cause chronic suppurative otitis media and to explain the condition's resistance to antibiotic treatment. 55 Recent evidence has demonstrated that pneumococcal biofilms with a high biofilm forming index exhibit greater resistance to azithromycin. 56 Effective eradication of biofilm infections requires killing both the bacteria and destruction of the matrix to minimise persistence of the viable organism. 57 Thus, persistent OM infections may arise from the failure to completely eradicate the original bacterial infection, 45 or the presence of biofilms 52 or, most recently, intracellular bacterial infection of the middle ear mucosal cells, particularly mucous secreting cells.
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Host response
The immune response in the middle ear to infection is characterised predominantly by an inflammatory response, which in the acute phase normally, results in clearance of infection, whilst low production IL-6 and high production TNF-α phenotypes contribute to OM risk during rhinovirus infection. 68 The association of certain genetic polymorphisms in TNFα, IL6, IL10, and TLR4 genotypes with increased susceptibility for otits media 68, 69, 70 would suggest that characteristics of the initial inflammatory response to infection may be crucial in setting the course for recurrent disease.
Importantly a number of environmental factors such as exposure to cigarette smoke and breastfeeding may further modify genetic risk.
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Management OM and antimicrobial resistance
Australian Therapeutic guidelines recommend antibiotics at initial consultation for infants diagnosed with AOM who are less than 6 months of age and for all Indigenous
Australian children with AOM. 71 However, given the high rate (80%) of self resolving episodes and minimal benefit of antibiotic treatment 72 in children who are not at high risk of developing complications, the prudent use of antibiotics is proposed 73 to minimise the rate of development of antibiotic resistant bacterial strains. Typically, a "wait and watch" approach, using analgesia to reduce acute pain is recommended for low risk children over 2 years of age 74 since 90% of children with AOM, treated with analgesia alone, recover in a few days. 75 Middle ear effusion normally resolves within 7 days in 40% of cases and 75-90% resolution occurs within 4 weeks. The continued high rate of antibiotic prescription is not justifiable on the basis of prophylactic administration to reduce the prevalence of OME since only marginal improvement (4%) has been observed in low risk children. 77 Children at high risk of OME such as Indigenous Australian children, are benefitted by increased return of normal middle ear function (9.6%) and reduced risks of tympanic perforation (14%) and pneumococcal carriage (12% Based on animal model studies 88 the possibility of developing a tribacterial (S.
pneumoniae, H. influenzae and M. catarrhalis) vaccine in the future is not beyond reality. 17 The inclusion of viral components in a future polymicrobial vaccine will come later.
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Experience from studies to date, suggest that the microbial ecology of the nasopharynx may be altered by vaccination 50, 90 particularly as the microbes targeted are often part of the normal commensal flora. In addition, with the introduction of pneumococcal conjugate vaccines it is generally accepted that with a decrease in vaccine serotypes there has been an overall reduction in the rate of detection of antibiotic resistance. 91 However, there is some evidence of an increase in the antibiotic resistance of non vaccine pneumococcal serotypes which could reduce the overall impact of pneumococcal conjugate vaccination on antibiotic resistance. 81 Hence, it will be necessary to establish ongoing surveillance studies to monitor any changes in the otopathogen profile and to continue to prescribe antibiotics cautiously for the treatment of OM. 
Conclusion
